Paul Rivard - 24 Aug 2023 Form 4 Insider Report for MyMD Pharmaceuticals, Inc. (TNFA)

Role: Chief Legal Officer
Signature: /s/ Paul Rivard
Issuer symbol: TNFA
Transactions as of: 24 Aug 2023
Net transactions value: +$166,500
Form type: 4
Filing time: 24 Aug 2023, 17:58:33 UTC
Previous filing: 18 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MYMD	Common stock	Purchase	$166,500	+150,000	+60%	$1.11	400,000	24 Aug 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.